Evaluation of the Predictors of Clinical and Radiological Response to Gamma-Knife Radiosurgery in the Treatment of Intermediate Ventral Nucleus of the Thalamus (VIM) Thalamotomy Tremor.

NCT ID: NCT03350139

Last Updated: 2017-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-23

Study Completion Date

2021-10-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gamma-Knife radiosurgery of the VIM for patients presenting with severe drug-resistant tremor is now current practice as an alternative to Deep Brain Stimulation (DBS) of the VIM.

Now, around 100 patients are treated annually in our unit (essential tremor or Parkinson tremor).

Clinical and radiological follow-up is demonstrating that 80% of these patients are presenting with a homogenous response complete or subtotal, the disappearance of the tremor mean delay of 6 months after radiosurgery. In neuroradiological responses on the MRI, is appearing roughly at the same time local contrast enhancement surrounding highty to signal no associated with clinical side effects.

In 15 to 20% of the patients, the clinical effets is not obtained and in the vast majority no MRI response or minimal MRI response is observed on images suggesting that these failures are related to specific resistance to radiosurgery of this subgroup.

In roughly 5% of the patients, at the contrary, hyper response is observe on the MRI rating clinically with side effects (hemiparesis or proprioceptive ataxia or dysarthria, hands problems….). The adverse effects are generally reversible either in whole or in part with the resorption of the perilesionnel oedema.

It would be extremely helpfull to be able to identify in advance these 2 groups of hyper and hypo respondeurs.

The capacity to identify in advance these patients at risk to hypo or hyper response would allow us to either contre-indicate radiosurgery or modify radiosurgery technicaly at the time of dose planing.

Sequently, these predictions would allow us to tailor individually mission management and information leading to improvment of the efficacy and tolerance of this kind of intervention.

The parameters suspected to be likely to influence the response are :

* genetics
* co-morbidities (diabetis, vascular…)
* Main aspect of the brain (severe atrophy, vascular, micro-infacts…)
* Chronobiological (timing during the day of the radiosurgical procedure)
* Associated medication (potential radioprotector or radiosensitizer effect of some drugs)
* Radiobiological (dose rate…)

The goal of this study is to collect all of these informations out of genetical one in the cohort of 700 patients having benefited ou will benefit from radiosurgery in the situation for essential tremor and parkinson disease. It will be test the predictive value of these parameters and the capacity to predict hyper or hypo response.

The work on the genetic material will take place in the second stage in the frame of a new different resarch project.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Disabling Tremor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients treated with gamma knife radiosurgery

Collection of non-genetic, chronobiological, therapeutic and co-morbidities

gamma knife radiosurgery

Intervention Type DEVICE

The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

gamma knife radiosurgery

The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 20 years minimum
* Patient with absolute contraindication or relative to deep brain stimulation (DBS) of VIM.
* Patient having the Gamma Knife radiosurgery of VIM (combining clinical and paraclinical conditions).
* Patient affiliated to a social security scheme.
* Patient having understood and signed the information notice for non opposition.

Exclusion Criteria

* Patient having a contraindication to performing a cerebral MRI (pace-maker, intracerebral metallic object etc.)
* Patient with a contraindication to radiosurgical treatment (previous treatment with cerebral radiotherapy)
* Vulnerable persons: minors, protected adults (guardianship or trusteeship) and adults unable to express their non-opposition.
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Olivier ARNAUD, General Director

Role: STUDY_DIRECTOR

Assistance Publique Hôpitaux de Marseille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assistance Publique Hôpitaux de Marseille

Marseille, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jean REGIS, PU-PH

Role: CONTACT

Phone: 491387058

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jean REGIS, PU-PH

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ID RCB

Identifier Type: REGISTRY

Identifier Source: secondary_id

2017-09

Identifier Type: -

Identifier Source: org_study_id